ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1462

Magnesium Is a New Mediator Arthritis Severity and Joint Damage

Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, rheumatoid arthritis, Rheumatoid arthritis (RA), Synovial Immune Biology, synovium and synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Animal Models - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Given the effects of magnesium supplementation in suppressing components of the innate immunity in short-term studies, we examined the effect of dietary magnesium modifications in arthritis severity, a chronic model of autoimmune disease.

Methods: DBA1/J mice were placed on one of two short-term diets before (22-day) the induction of collagen-induced arthritis (CIA) or after disease onset (9-days): low-magnesium diet or normal diet. The diets were then discontinued and converted into a normal diet. CIA activity and arthritis severity was scored for 50 days. Spleens were used for qPCR and FACS, and synovial tissues and cells lines for qPCR.

Results:  Mice on the low magnesium diets were significantly protected and had a >70% lower mean arthritis severity scores in the preventive arm. The group that started the low magnesium diet after the onset of disease also achieved a 50% reduction on their mean severity. The disease protective or ameliorating effects of the low magnesium diet persisted beyond the duration of the diet suggesting a permanent effect on a critical pathogenic pathway. The low magnesium diet mice preserved a normal joint histology without erosive changes. Mice on the low-magnesium diet had significantly reduced synovial tissue expression of IL-6, IL-17, CXCL10, RORA and RORC (genes required or implicated in the development of Th17 T cells), as well as reduced levels of MMP-2 and MMP-3, which are two key mediators of joint damage. Low magnesium concentrations also reduced synovial fibroblast expression of TNFa and IL-6. Spleens from low magnesium diet mice had reduced levels of Th17 T cells and increased numbers of FoxP3+ Treg cells and increased number of IL-10+ CD4+ T cells. In vitro studies demonstrated that low magnesium concentrations (0.1mM and 0.4mM) did not directly affect the differentiation of mouse naïve CD4+ T cells into Th17 T cells, nor affected the amount of IL-17 produced by these cells, suggesting an indirect effect mediated by another cell type.

Conclusion:  This study revealed a novel role for magnesium in the regulation of autoimmune arthritis and opens new possibilities for the treatment of autoimmune diseases such as RA and psoriatic arthritis with short courses of dietary or drug-induced modulations of magnesium levels. We also describe a new effect of low magnesium in suppressing Th17-related genes and MMPs.


Disclosure: T. Laragione, None; N. Azizgolshani, None; C. Harris, None; E. Gao, None; P. Gulko, None.

To cite this abstract in AMA style:

Laragione T, Azizgolshani N, Harris C, Gao E, Gulko P. Magnesium Is a New Mediator Arthritis Severity and Joint Damage [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/magnesium-is-a-new-mediator-arthritis-severity-and-joint-damage/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnesium-is-a-new-mediator-arthritis-severity-and-joint-damage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology